• Syntrix Completes Initial SX-682 Dosing in Cancer Trial Campaign americanpharmaceuticalreview
    November 05, 2020
    Syntrix Pharmaceuticals has completed initial SX-682 dosing in Phase 1/2 trials in myelodysplastic syndromes (MDS) and metastatic melanoma. The drug was well tolerated and absorbed with excellent dose-proportional drug levels in blood.
PharmaSources Customer Service